

Freeform Search

Database:	<div style="border: 1px solid black; padding: 2px;"> US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins </div>
Term:	<div style="border: 1px solid black; padding: 2px;"> L10 NOT L8 </div>
Display:	<div style="border: 1px solid black; padding: 2px;"> 20 Documents in Display Format: CIT Starting with Number 1 </div>
Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

Search
Clear
Interrupt

Search History

DATE: Sunday, October 14, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L11</u>	L10 NOT L8	4	<u>L11</u>
<u>L10</u>	L9 and @ad<20020913	9	<u>L10</u>
<u>L9</u>	L6 and nasal\$4	32	<u>L9</u>
<u>L8</u>	L7 and @ad<20020913	5	<u>L8</u>
<u>L7</u>	L6 same aloe	14	<u>L7</u>
<u>L6</u>	L5 same (camphor or "eucalyptus oil" or menthol or azulen)	142	<u>L6</u>
<u>L5</u>	L4 same (hydroxyethylcellulose or HEC or glycerine or glycerin or carrageenan or sugar or "guar gum" or MC or methylcellulose or thicken\$4)	15268	<u>L5</u>
<u>L4</u>	carrier same (glycerin or glycerine)	15268	<u>L4</u>
<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>			
<u>L3</u>	(Charles near Hensley) AND @pd>20060718	4	<u>L3</u>
<u>L2</u>	(Tim near Clarot) AND @pd>20060718	6	<u>L2</u>
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L1</u>	7115275.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

E 'HOME' ENTERED AT 15:12:43 ON 14 OCT 2007)

FILE 'CAPLUS, MEDLINE, USPATFULL, BIOSIS' ENTERED AT 15:13:02 ON 14 OCT 2007

L1 8875 S CARRIER (P) (GLYCERIN OR GLYCERINE)
L2 4081 S L1 (S) (NASAL? OR NOSTRIL OR INTRANASAL? OR NOSE)
L3 4081 S L2 (S) (HYDROXYETHYLCELLULOSE OR HEC OR GLYCERINE OR GLYCERI
L4 474 S L3 (S) (CAMPHOR OR EUCALYPTUS(W)OIL OR MENTHOL OR AZULEN)
L5 127 S L4 (S) ALOE
L6 17 S L5 NOT PD>20020913
L7 17 DUP REM L6 (0 DUPLICATES REMOVED)
L8 109 S L5 AND (SYSTEM OR APPLICATOR)
L9 109 S L8 AND ALOE
L10 14 S L9 NOT PD>20020913
L11 14 DUP REM L10 (0 DUPLICATES REMOVED)
L12 0 S L11 NOT L7

L7 ANSWER 1 OF 17 USPATFULL on STN

TI Substituted heterocyclic compounds for treating multidrug resistance
AB Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed. Suitable substituted heterocyclic compounds include: ##STR1##

L7 ANSWER 2 OF 17 USPATFULL on STN

TI Absorbent articles with hydrophilic compositions containing botanicals
AB The present invention relates to compositions and absorbent articles including compositions for protecting the skin barrier. The compositions can be applied to the bodyfacing surfaces of absorbent articles so that the compositions come into contact with the skin. The compositions of the invention have improved stability on the bodyfacing surfaces after processing. The compositions of the invention provide several benefits including prevention and alleviation of skin irritations associated with the use of absorbent articles. The compositions can include hydrophilic solvents, high molecular weight polyethylene glycols, fatty alcohols, fatty acids and extracted botanical actives.

L7 ANSWER 3 OF 17 USPATFULL on STN

TI Absorbent articles with hydrophilic compositions containing anionic polymers
AB The present invention relates to compositions and absorbent articles including compositions for protecting the skin barrier. The compositions can be applied to the bodyfacing surfaces of absorbent articles so that the compositions come into contact with the skin. The compositions of the invention have improved stability on the bodyfacing surfaces after processing. The compositions of the invention provide several benefits including prevention and alleviation of skin irritations associated with the use of absorbent articles. The compositions can include hydrophilic solvents, high molecular weight polyethylene glycols, fatty alcohols, fatty acids and decoupling polymers.

L7 ANSWER 4 OF 17 USPATFULL on STN

TI Acyclic compounds and methods for treating multidrug resistance
AB Substituted acyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted acyclic compound has the formula: ##STR1##

L7 ANSWER 5 OF 17 USPATFULL on STN

TI Compounds having heterocyclic groups containing two nitrogen atoms for treating multidrug resistance
AB Compounds having heterocyclic groups containing two nitrogen atoms are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable compound has the formula: ##STR1##

L7 ANSWER 6 OF 17 USPATFULL on STN

TI 2-substituted heterocyclic compounds for treating multidrug resistance
AB Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds. An example compound has the formula: ##STR1##

L7 ANSWER 7 OF 17 USPATFULL on STN

TI Substituted bicyclic compounds for treating multidrug resistance
AB Substituted bicyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted bicyclic compounds are disclosed. Suitable substituted bicyclic compounds include: ##STR1##

L7 ANSWER 8 OF 17 USPATFULL on STN
TI Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
AB A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

L7 ANSWER 9 OF 17 USPATFULL on STN
TI Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AB A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.

L7 ANSWER 10 OF 17 USPATFULL on STN
TI Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
AB Substituted heterocyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted heterocyclic compound has the formula: ##STR1##.

L7 ANSWER 11 OF 17 USPATFULL on STN
TI Antimicrobial treatment for herpes simplex virus and other infectious diseases
AB An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.

L7 ANSWER 12 OF 17 USPATFULL on STN
TI Heterocyclic 2-substituted ketoamides
AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

L7 ANSWER 13 OF 17 USPATFULL on STN
TI COSMETIC COMPOSITIONS
AB The invention relates to a cosmetic composition comprising: (i) greater than 2% of a panthenol oil regulating agent; and (ii) from 0.1 % to 10% of a particulate, oil-absorbing polymer, and (iii) from 20% to 97.9% of a cosmetically acceptable carrier. The compositions, which preferably take the form of oil-in-water emulsions, provide both immediate and long-term control of oily and/or shiny skin.

L7 ANSWER 14 OF 17 USPATFULL on STN
TI Heterocyclic 2-substituted ketoamides
AB The present disclosure describes novel compounds and compositions which

are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

L7 ANSWER 15 OF 17 USPATFULL on STN

TI 2-substituted heterocyclic sulfonamides

AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

L7 ANSWER 16 OF 17 USPATFULL on STN

TI Antimicrobial compositions comprising a benzoic acid analog and a metal salt

AB The present invention relates to antimicrobial compositions which provide enhanced immediate as well as residual anti-viral and antibacterial efficacy. The antimicrobial compositions of the present invention provide previously unseen residual effectiveness against Gram negative bacteria, Gram positive bacteria, and viruses, fungi, and improved immediate germ reduction upon use. These compositions comprise: a) a safe and effective amount of a benzoic acid analog; b) a safe and effective amount of a metal salt; and c) a dermatologically acceptable carrier for the acid and salt wherein said composition has a pH of from about 1 to about 7. The invention further relates to methods of use for the present compositions as well as antimicrobial products which incorporate the compositions.

L7 ANSWER 17 OF 17 USPATFULL on STN

TI Inhalation therapy decongestant with foraminous carrier

AB A vaporizable decongestant is supported and stabilized on a flexible foraminous carrier composed typically of open-cell plastic foam, cloth or other fibrous material such as nonwoven fabric. The term "foraminous" herein is intended to refer to a substance or medium containing minute openings or perforated by many minute apertures. The decongestant is placed on the surfaces within the interstices and minute apertures or on fibers from which the foraminous carrier is formed. Vaporization of the inhalable decongestant is facilitated by providing the potential for greatly increasing its exposed surface area. Distributing the decongestant composition over the large, expanded surface within the foraminous carrier is beneficial in enhancing both the volatilization and evaporation of the decongestant agent. It also prolongs the useful life of the product. Once vaporized, the aromatic decongestant is available for natural inhalation through the nose or mouth to help relieve one or more of the symptoms of cough, colds, nasal or chest congestion and related symptoms. The foraminous carrier is preferably provided in the form of a patch or sheet that is bonded to the skin to serve as a supporting base for the active decongestant agent. The patch defining the carrier is typically adhesively bonded to the upper part of the body, e.g. on the face, neck or chest, in a location where the decongestant is liberated into the air and can be inhaled through the mouth or nose.



Day : Sunday
Date: 10/14/2007
Time: 14:58:50

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Refine Search

Search Results -

Terms	Documents
L9 and @ad<20020913	0

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, October 14, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L10</u>	L9 and @ad<20020913	0	<u>L10</u>
<u>L9</u>	L8 and glycerin	17	<u>L9</u>
<u>L8</u>	L1 and decongestant	24	<u>L8</u>
<u>L7</u>	L6 and @ad<20020913	0	<u>L7</u>
<u>L6</u>	L5 and glycerin	16	<u>L6</u>
<u>L5</u>	L1 and oxymetazoline	17	<u>L5</u>
<u>L4</u>	L3 and @ad<20020913	0	<u>L4</u>
<u>L3</u>	L2 and glycerin	11	<u>L3</u>
<u>L2</u>	L1 same oxymetazoline	11	<u>L2</u>
<u>L1</u>	aloe same (\$4nasal\$4 or nose or nostril)	606	<u>L1</u>

END OF SEARCH HISTORY

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database
	US Patents Full-Text Database
	US OCR Full-Text Database
	EPO Abstracts Database
	JPO Abstracts Database
	Derwent World Patents Index
	IBM Technical Disclosure Bulletins

Term:	L5 NOT L3	▲
		▼

Display:	<input type="text" value="20"/>	Documents in Display Format:	<input type="text" value="CIT"/>	Starting with Number	<input type="text" value="1"/>
-----------------	---------------------------------	-------------------------------------	----------------------------------	-----------------------------	--------------------------------

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

Search History

DATE: Sunday, October 14, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L6</u>	L5 NOT L3	17	<u>L6</u>
<u>L5</u>	L4 and @ad<20020913	19	<u>L5</u>
<u>L4</u>	L1 and (\$5nasal\$5 or nose or nostril)	40	<u>L4</u>
<u>L3</u>	L2 and @ad<20020913	2	<u>L3</u>
<u>L2</u>	L1 same (\$5nasal\$5 or nose or nostril)	12	<u>L2</u>
<u>L1</u>	liposome same (decongestant or "oxymetazoline hydrochloride" or "naphazoline hydrochloride" ephedrine or "phenylephrine hydrochloride" or "xylometaxoline hydrochloride" or camphor or "eucalyptus oil" menthol or azulen)	96	<u>L1</u>

END OF SEARCH HISTORY